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Reconstructing Vision: Undone Science and Anti-VEGF treatment of Wet Agerelated Macular Degeneration
Abstract
Treatment of wet AMD with the anti-VEGF drug Lucentis can be vital to maintaining central vision and
therefore quality of life. This drug treatment is heavily subsidised by the Australian Government. In 2009
over $150 million was spent by the Australian Government’s Pharmaceutical Benefits Scheme on this
particular AMD treatment drug. Yet, while a cheaper drug exists which costs less than one tenth of this
price to treat wet AMD, the Australian Government’s own policies and the apparent lack of scientific
testing of the cheaper anti-VEGF drug (Avastin) means that it will be some time before cheaper drugs are
available through the Australian health system. There is little incentive for the pharmaceutical and
biotechnology companies to conduct costly research into cheaper drug options and health systems
across the developed world have faced various barriers to conducting their own clinical trials on cheaper
drugs. This dilemma is an example of what is known as the problem of undone science (Hess 2006),
where here the lack of research on Avastin as a treatment of wet AMD has held back the reform of drug
treatments for wet AMD. This brief working paper seeks to investigate how the undone science of
medical retinal drug treatments came to influence the options available to treat someone experiencing
wet AMD, and more broadly, how the problem of undone science can shape the financial and treatment
burden of Age-related Macular Degeneration on the Australian community.
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1. Tom Cleary
Reconstructing Vision: Undone Science and Anti-VEGF treatment of Wet
Age-related Macular Degeneration
Abstract
Treatment of wet AMD with the anti-VEGF drug Lucentis can be vital to maintaining central
vision and therefore quality of life. This drug treatment is heavily subsidised by the
Australian Government. In 2009 over $150 million was spent by the Australian
Government’s Pharmaceutical Benefits Scheme on this particular AMD treatment drug. Yet,
while a cheaper drug exists which costs less than one tenth of this price to treat wet AMD, the
Australian Government’s own policies and the apparent lack of scientific testing of the
cheaper anti-VEGF drug (Avastin) means that it will be some time before cheaper drugs are
available through the Australian health system.
There is little incentive for the pharmaceutical and biotechnology companies to conduct
costly research into cheaper drug options and health systems across the developed world have
faced various barriers to conducting their own clinical trials on cheaper drugs. This dilemma
is an example of what is known as the problem of undone science (Hess 2006), where here
the lack of research on Avastin as a treatment of wet AMD has held back the reform of drug
treatments for wet AMD.
This brief working paper seeks to investigate how the undone science of medical retinal drug
treatments came to influence the options available to treat someone experiencing wet AMD,
and more broadly, how the problem of undone science can shape the financial and treatment
burden of Age-related Macular Degeneration on the Australian community.

The role of social theory in the reshaping of primary care
Health professionals take pride in the ongoing search for best practice. Often evidence based
studies are performed that demand the practitioner rethink their approach to an area of

expertise. Most times these studies come from an area of scientifically recognised research,
but social theory can also influence the way a health practitioner can think. For example, an
awareness of the societal and historical aspects of the technoscientific practices that
optometry inhabits, and the way social theory can help explain and interpret the changes that
are taking place is becoming more important as social change occurs more rapidly and in ever
more complex ways.
Each clinical encounter is an opportunity to apply and adapt best practice both within the
clinic and in the society at large. This is because in primary care optometry we meet the
individual statistics that make up the construct of epidemiological thinking mediated by
health statistics and models. This encounter has multiple truths. A clinical encounter is
mediated by communication occurring in an essentially social space which is an area where
the tools provided by social theory can find immediate application. Social reconstruction is a
process offered by recent social theorist that in some ways invites a re-thinking of the way
technoscientific practices are justified. It is a process that involves critical analysis of recent
historical cases used in such diverse areas of greening of industries, non-weapon based
defence and alternative medicine. Reconstruction of a social practice, especially a
technoscientific social practice which can be so prone to technocratic absolutism, is an idea
that can be important to achieving significant reform. If we continue to make the same
underlying comfortable assumptions and do not challenge the status quo with new ideas then
there is little hope for the evolution of social practices to fit the requirements of the society
that creates and sustains them.

In the context of this study a partisan approach was used which hoped to see reform of the
case study area of Anti- VEGF treatment and treatment research. Treatment of wet AMD was
approached a quality of life issue where effective treatment is highly valued. Lucentis
treatment of wet AMD is heavily subsidized in Australia and yet treatment with another AntiVEGF drug Avastin, has faced unique challenges. David Hess’ concept of undone science
was applied to this comparative case study of Anti-VEGF wet AMD treatments. The
application of the concept of undone science came as a result of analysis of Anti-VEGF
treatment options from 2005 up to 2010. At certain stages during this period the main
problem with Avastin use was the lack of comprehensive clinical trials research, hence the
problem of undone science for those who may have wished to justify its use as a treatment for
wet AMD.
This case study of Anti-VEGF treatment research gave an opportunity to apply David Hess’
concept of undone science. Hess’ work in this field examines how certain societal aspects of
conducting research can create a process of uneven development.
In Hess’(2006) chapter Antiangiogenesis Research and the Dynamics of Scientific Fields he
identifies certain factors as important to the study of Undone Science: Denaturalization of the
material world, Universalization of values, Expansion of scale and Differentiation of
institutions.

When describing denaturalization of the material world Hess identifies that science and
technology can tend to become more distanced from living entities over time.
Denaturalization is important to the historical context of the emergence of Anti-VEGF drugs
as a treatment of unwanted blood vessel growth. The discussion of denaturalization is an idea
that is also leads to an understanding of the importance of identifying patentable substances,
as opposed to substances that may be effective but are deemed to natural to be patented and
therefore more difficult to converted into a successful drug treatment. In the case of Lucentis
where this drug was produced specifically for the treatment of retinal blood vessels the
question of patent was uncomplicated and the ease of predicting an economic return meant
that research was able to be funded. On the other-hand Avastin was already available as
treatment of bowel cancer when it began to be used to treat retinal blood vessel growth. This
meant that any research that was conducted on Avastin as a wet AMD treatment would need
to be performed without the expectation of the same economic returns as Lucentis. Also as
successful Avastin research would hurt the profitability of Lucentis it is not surprising that the
company conducting Lucentis research would not support the funding of Avastin research. By
denaturalizing the material world and creating patentable substances we can see in this case
how the priority can quickly become conducting research in the most economically
productive areas of a scientific field.
Hess also describes the universalization of values, a tendency for fields of science to develop
formal methodologies of dispute resolution such as the use of Randomised Controlled Trials
(RCTs) in the area of clinical medicine. RCTs are recognized as the gold standard for
evaluating treatment but also impose large costs and scale requirements on the required
research. This makes the imperative to use the most economically viable substance more
important when looking to make a profit on investment in drug treatment options. Phase I, II
and III drug trials can cost many millions of dollars and are seen as important to ensure that
new drug treatments are safe and effective. These experiments are conducted in a way that
attempts to minimise certain forms of bias. But the social factors at play in undone science
are rarely taken into account when addressing the case for and against using particular drug
treatments. For example it may be the case that comprehensive research has not been
conducted on Avastin as a treatment for wet AMD, the clinician that wished to justify using
this drug may point to the way that due to the social circumstances of this area of undone
science the potential bias of the observer is not the only bias to take into account when
evaluating the relevant research. The societal factors at play also need to be addressed in the
way they shape the research available to the clinician.
Expansion of scale is also identified by Hess as shaping the contours of research, where the
cost and scale of laboratory sciences has expanded faster than the ability of public institutions
to fund research.As the cost and scale has out paced the public purse this has led to the
involvement of many more institutions and organizations to bring new science to the public.
Many of these organizations are only involved in order to realize a financial return on their
investment. Thus the way these organizations go about their business can further shape the
contours of scientific progress. This can be demonstrated in the case of the privately funded
Lucentis and the public funding of Avastin wet AMD treatment research. The expansion of

scale means that it is not always possible to conduct research in areas that are for the common
good.
So in scientific fields there can be lots of organizations, both public and private and large
amounts of money at stake. Hess shows the importance of the differentiation of these
institutions in shaping science. Hess points out that conflicts regarding roles and
organizational goals increasingly arise within and between various fields of action of science.
In the case study of Lucentis and Avastin this differentiation of institutions has been identified
as a challenge and an opportunity for bringing about organizational and political change that
can help institutions evolve to the changing needs of the community. For example, the way
public institutions such as hospitals and professional organisations can bring about reform of
a scientific field by cooperating in ways that address the lack of research in an area where
there is little hope of a financial return but huge cost savings for the community. Avastin may
not be as profitable a treatment of wet AMD as Lucentis but this does not mean that the
potential benefits of this treatment are not a good reason for institutions to cooperate in order
to fund and conduct the relevant research.
Overall an awareness of societal and historical aspects of technoscientific practices has been
shown in recent literature to be important in the progress of science and the modernization of
society. Hess’ study of undone science when applied to this case of Anti-VEGF treatment of
wet AMD, is a robust example of how societal factors can be the key consideration for people
in their everyday encounter with clinical best practice. An understanding of the implications
of denaturalization of the material in the current era of patent for profit is important for those
seeking reform. Also finding ways to break down way the problems of institutional
differentiation, expansion of scale and universalization of values is becoming essential when
trying to find ways to resolve disputes. Thus an ongoing examination of the way that progress
in biosciences can be interpreted in terms of social theory such as that of Hess’ undone
science is also important for community at large.
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